Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue , 2016, Pages 1-18

  Dauden E ^a   Puig, L ^b   Ferrandiz C ^c   Sanchez Carazo J L ^d   Hernanz Hermosa, J M ^e  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; COMORBIDITY; CONSENSUS; DELPHI STUDY; DERMATOLOGIST; DISEASE SEVERITY; FOLLOW UP; HEALTH SURVEY; HUMAN; MAINTENANCE THERAPY; MEDICAL SOCIETY; PATIENT CARE; PATIENT COMPLIANCE; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RELAPSE; SCREENING; SPAIN; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CONSENSUS DEVELOPMENT; DERMATOLOGY; EVIDENCE BASED MEDICINE; ORGANIZATION; PROCEDURES; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; VENEREOLOGY;

ACADEMIES AND INSTITUTES; BIOLOGICAL THERAPY; CONSENSUS; DERMATOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SPAIN; VENEREOLOGY;

EID: 84957672550     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13542     Document Type: Article

References (64)

1. Steurer J,. The Delphi method: an efficient procedure to generate knowledge. Skeletal Radiol 2011; 40: 959-961.
2. Boehncke WH, Brasie RA, Barker J, et al,. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006; 20: 988-998.
3. Ståhle M, Atakan N, Boehncke WH, et al,. Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges 2010; 8: 812-818.
4. Puig L, Ribera M, Hernanz JM, et al,. Treatment of scalp psoriasis: review of the evidence and Delphi consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2010; 10: 827-846.
5. Mrowietz U, de Jong EM, Kragballe K, et al,. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014; 28: 438-453.
6. Langley RG, Saurat JH, Reich K,; Nail Psoriasis Delphi Expert Panel. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol 2012; 26: 373-381.
7. Cañete JD, Daudén E, Queiro R, et al,. Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study. Actas Dermosifiliogr 2014; 105: 216-232.
8. Richard MA, Barnetche T, Horreau C, et al,. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013; 27 (Suppl. 3): 2-11.
9. Reich K, Griffiths C, Barker J, et al,. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008; 217: 268-275.
10. Fernández-Sueiro JL, Juanola Roura X, Cañete Crespillo Jde D, et al,. Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. Reumatol Clin 2011; 7: 179-188.
11. Paul C, Gallini A, Maza A, et al,. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 2): 2-11.
12. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
13. Nast A, Boehncke WH, Mrowietz U, et al,. S3 Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG 2012; 10 (Suppl. 2): S1-S95.
14. Nast A, Kopp I, Augustin M, et al,. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138.
15. Nast A, Kopp I, Augustin M, et al,. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5 (Suppl. 3): 1-119.
16. Pathirana D, Nast A, Ormerod AD, et al,. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol 2010; 24: 1458-1467.
17. Leeb BF, Bottcher E, Brezinschek HP, et al,. The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus Project. Clin Rheumatol 2010; 29: 167-174.
18. Linder D, Sampogna F, Torreggiani A, et al,. Psodisk, a new visual method for assessing the burden of psoriasis on patients. J Eur Acad Dermatol Venereol 2012; 26: 1163-1166.
19. Langley RG,. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data? J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 2): 21-29.
20. Puig L, Bordas X, Carascosa JM, et al,. Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis was published by the Spanish Psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2009; 100: 277-286.
21. Linstone HA, Turoff M, eds. The Delphi Method: Techniques and Applications. Addison-Wesley, Reading, MA, 1975: 291-321.
22. Hsu S, Papp KA, Lebwohl MG, et al,. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95-102.
23. Puig L, Carrascosa JM, Dauden E, et al,. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr 2009; 100: 386-413.
24. Schmitt J, Wozel G,. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-199.
25. Puzenat E, Bronsard V, Prey S, et al,. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 10-16.
26. Mrowietz U, Kragballe K, Nast A, Reich K,. Strategies for improving the quality of care in psoriasis with the use of treatment goals-a report on an implementation meeting. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 3): 1-13.
27. Paul C, Gourraud PA, Bronsard V, et al,. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 2-9.
28. Both H, Essink-Bot ML, Busschbach J, Nijsten T,. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 2726-2739.
29. Bronsard V, Paul C, Prey S, et al,. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 17-22.
30. Krueger GG, Feldman SR, Camisa C, et al,. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285.
31. Finlay AY,. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
32. Smith CH, Anstey AV, Barker JNWN, et al,. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
33. SOLAPSO (Sociedad Latinoamericana de Psoriasis). Latin American Consensus on Psoriasis. Treatment guidelines. 2009 update. Revista Latinoamericana de Psoriasis y Artritis Psoriasica 2010; 1: 1-55.
34. Pariser DM, Bagel J, Gelfand JM, et al,.; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007; 143: 239-242.
35. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J,. Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011; 15: 210-219.
36. Garcia-Doval I, Carretero G, Vanaclocha F, et al,. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.
37. Puig L, Carrascosa JM, Carretero G, et al,. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Actas Dermosifiliogr 2013; 104: 694-709.
38. Puig L,. Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. J Eur Acad Dermatol Venereol 2013; 27: e257-e260.
39. Greenberg JD, Kremer JM, Curtis JR, et al,. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. An Rheum Dis 2011; 70: 576-582.
40. Boehncke WH, Salgo R, Garbaraviciene J, et al,. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.
41. Nast A, Gisondi P, Omerod AD, et al,. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015- Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015 Oct 19. doi: 10.1111/jdv.13354.
42. Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT,. Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol 2013; 69: 25-33.
43. Sánchez-Moya AI, Daudén E,. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment. Arch Dermatol 2012; 148: 1332-1333.
44. Tsai TF, Chiu HY, Song M, Chan D,. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 2013; 168: 444-446.
45. Tsai TF, Ho V, Song M, et al,. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167: 1145-1152.
46. Sánchez-Moya AI, García-Doval I, Carretero G, et al,. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol 2013; 27: 1366-1374.
47. American Academy of Dermatology Work Group, Menter A, Korman NJ, et al,. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-174.
48. Navarro R, Vilarrasa E, Herranz P, et al,. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168: 609-616.
49. Cansu DU, Kalifoglu T, Korkmaz C,. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35: 421-424.
50. Renzi C, Di Pietro C, Gisondi P, et al,. Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. Acta Derm Venereol 2006; 86: 528-534.
51. Bewley A, Page B,. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 4): 9-14.
52. Heffernan MP,. Combining traditional systemic and biologic therapies for psoriasis. Semin Cutan Med Surg 2010; 29: 67-69.
53. Ortiz A, Yamauchi PS,. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. Skinmed 2006; 5: 285-288.
54. Carrascosa JM, Vilavella M, García-Doval I, et al,. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2014; 28: 907-914.
55. Daudén E, Castañeda S, Suarez C, et al,. Integrated approach to comorbidity in patients with psoriasis. Actas Dermosifiliogr 2012; 103 (Suppl. 1): 1-64.
56. Daudén E, Castañeda S, Suárez C, et al,. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 1387-1404.
57. Prey S, Paul C, Bronsard V, et al,. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 23-30.
58. Landells I, MacCallum C, Khraishi M,. The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett 2008; 13: 4-7.
59. Anandarajah AP, Ritchlin CT,. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol 2009; 5: 634-641.
60. Reich K,. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 2): 3-11.
61. Boehncke WH, Buerger C, Boehncke S,. [Co-morbidities in psoriasis vulgaris]. Hautarzt 2009; 60: 116-121. (in German).
62. Kimball AB, Gladman D, Gelfand JM, et al,. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042.
63. Horreau C, Pouplard C, Brenaut E, et al,. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27 (Suppl. 3): 12-29.
64. Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA,. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res 2012; 304: 7-13.